RMD Open
(Apr 2021)
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases
Ulf Mueller-Ladner,
Karen Schreiber,
Nico M Wulffraat,
Victoria Furer,
Christien Rondaan,
Nancy Agmon-Levin,
Sander van Assen,
Marc Bijl,
Meliha Crnkic Kapetanovic,
Klaus Warnatz,
Ori Elkayam,
Annette de Thurah,
Daphna Paran
Affiliations
Ulf Mueller-Ladner
25 Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Campus Kerckhoff, Bad Nauheim, Germany
Karen Schreiber
Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark
Nico M Wulffraat
2 Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands
Victoria Furer
1Tel Aviv University, Tel Aviv-Yafo, Israel
Christien Rondaan
2University of Groningen, Groningen, Netherlands
Nancy Agmon-Levin
Clinical Immunology, Angioedema and Allergy Unit, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel
Sander van Assen
24 Internal medicine (infectious diseases), Treant Care Group, Hoogeveen, The Netherlands
Marc Bijl
2University of Groningen, Groningen, Netherlands
Meliha Crnkic Kapetanovic
Department of Clinical Science, Skåne University Hospital Lund, Lund, Skåne, Sweden
Klaus Warnatz
22 Centre for Chronic Immunodeficiency, University Medical Centre Freiburg, Freiburg, Germany
Ori Elkayam
Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Annette de Thurah
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Daphna Paran
1Tel Aviv Sourasky Medical Center, Department of Rheumatology, Tel Aviv-Yafo, Israel
DOI
https://doi.org/10.1136/rmdopen-2021-001594
Journal volume & issue
Vol. 7,
no. 1
Abstract
Read online
In view of the COVID-19 pandemic, there is an unmet clinical need for the guidelines on vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). This position paper summarises the current data on COVID-19 infection in patients with AIIRD and development of vaccines against COVID-19, discusses the aspects of efficacy and safety of vaccination, and proposes preliminary considerations on vaccination against COVID-19 in patients with AIIRD, mainly based on the expert opinion and knowledge on the use of other vaccines in this population of patients.
WeChat QR code
Close
